These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25130822)

  • 1. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
    Zhang Y; Xiao C; Gu SC; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
    Qin Y; Liu H; Ruan S; Cai YF; You XF; Song GQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
    Remacha ÁF; Arrizabalaga B; Villegas A; Durán MS; Hermosín L; de Paz R; Garcia M; Diez Campelo M; Sanz G;
    Ann Hematol; 2015 May; 94(5):779-87. PubMed ID: 25516455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of iron metabolism indicators in ineffective hematopoiesis of myelodysplastic syndrome].
    Yang Y; Yang B; Liang ZP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):948-52. PubMed ID: 23998591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients.
    Zhang Y
    Hematology; 2020 Dec; 25(1):1-10. PubMed ID: 31838956
    [No Abstract]   [Full Text] [Related]  

  • 6. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.
    Gu S; Song X; Zhao Y; Guo J; Fei C; Xu F; Wu L; Zhang X; Zhao J; Chang C; Li X
    Hematology; 2013 Sep; 18(5):286-94. PubMed ID: 23540794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry.
    Neukirchen J; Fox F; Kündgen A; Nachtkamp K; Strupp C; Haas R; Germing U; Gattermann N
    Leuk Res; 2012 Aug; 36(8):1067-70. PubMed ID: 22564985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of iron chelation therapy on allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome patients with iron overload].
    Gu CH; Li CX; Ye L; Liu H; Ma JF; Wang T; Zou Q; Chen J; Chen XC; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):189-93. PubMed ID: 27033754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelation therapy in MDS: what have we learnt recently?
    Schmid M
    Blood Rev; 2009 Dec; 23 Suppl 1():S21-5. PubMed ID: 20116636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms.
    Breccia M; Voso MT; Aloe Spiriti MA; Fenu S; Maurillo L; Buccisano F; Tafuri A; Alimena G
    Ann Hematol; 2015 May; 94(5):771-7. PubMed ID: 25743685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients.
    Zadrazil J; Horák P; Horcicka V; Zahálková J; Strébl P; Hrubý M
    Kidney Blood Press Res; 2007; 30(2):108-16. PubMed ID: 17374961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
    Wong SA; Leitch HA
    Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.